Wed, Sep 17, 2014, 2:05 AM EDT - U.S. Markets open in 7 hrs 25 mins

Recent

% | $
Quotes you view appear here for quick access.

BioCryst Pharmaceuticals, Inc. Message Board

  • jack_hemmer_rides_on jack_hemmer_rides_on Apr 9, 2013 2:32 PM Flag

    Cumulative effect ..

    Although this H7N9 has been errantly pumped to the extreme with EVERY point incorrect.. and I don't believe this out break will have any effect in the U.S. .. it is possible that the accumulation of possible threats would cause our govt. to eventually respond. Unless the H7N9 achieves h-h-h ability..it's likely to have no effect on us.
    However, the H3N2 was difficult this year.. and the growing resistance in Australia could pose a problem this fall. Will our govt. act preemptively? WTH knows? .. but they should.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • How many months will be needed to get a "shot" here? 6 to 8 months....If this stock was go great in every aspect then it would have been taken out by now....and yet it is still being used as a pump and dump over and over again. Move over to NVAX who has a paying partner and some very nice products that are in demand. Why the 8.85% drop here today....maybe people doing their DD!

      Sentiment: Strong Sell

    • ISID Promed mail reports an infant H5N1 death, so we have both H7N9 and H5N1 circulating in avian and human populations. Continued govt inaction to approve and stock peramivir verges on reckless disregard of public health because it is most effective immediately.

      St. Jude's research in 2007 found peramivir effective against H5N1, and researchers said
      "Our findings support the use of peramivir during a pandemic, and we are currently studying the emergence of H5N1 variants that are resistant to this drug and may occur in the course of treatment," said Natalia A. Ilyushina, Ph.D., a postdoctoral fellow in Webster's laboratory. Ilyushina is a co-author

      The researchers reported 100 percent survival among 10 infected mice given intramuscular injections of peramivir daily for eight days. The drug also inhibited replication of the deadly strain of H5N1 virus in the lung, brain and spleen. The key to the high survival rate was treating the infected mice within 24 hours after infection with H5N1 and continuing the treatment for eight days. In contrast, a single intramuscular injection resulted in a 40 percent survival rate, while two intramuscular injections increased the rate to 60 percent. The single intramuscular injection did not completely inhibit H5N1 virus replication in the lungs and spleen, but did decrease the spread of virus to the brain.
      "Peramivir should be given as soon as H5N1 infection is suspected, since onset of symptoms in infected humans can be delayed," said David A. Boltz, Ph.D., a postdoctoral fellow... "The drug could also be given as a preventive measure during an outbreak to decrease the risk of infection," he said. Boltz is first author of a paper....at the 20th International Conference on Antiviral Research
      "We were surprised to see a 40 percent survival rate among mice after just a single dose of peramivir," said Elena A. Govorkova, Ph.D., a scientific manager in the Infectious Diseases department at St. Jude. Govorkova is paper's senior author

    • So, what is your advice to investors, should they wait until after the approval?

 
BCRX
11.34-0.11(-0.96%)Sep 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.